November was yet another profitable month to be an investor in Array BioPharma (NASDAQ: ARRY). Shares of the cancer-focused clinical-stage biopharma gained more than 32% during the period, according ...
A stock that quadruples in 12 months makes investors happy campers. That's exactly what Array BioPharma (NASDAQ: ARRY) has done. And most of those impressive gains came over the last six months. Some ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果